REG - OptiBiotix Health - Confirmation of Director appointments to the Board <Origin Href="QuoteRef">OPTIO.L</Origin>

OptiBiotix HealthAnnouncement

15/03/2017 07:07

RNS Number : 4533Z
OptiBiotix Health PLC
15 March 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
15 March 2017
Confirmation of Director appointments to the Board
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that further to the announcements dated 5 January 2017 and 18 January 2017 and completion of the normal regulatory due diligence, Per Rehn and Christina Wood have been appointed to the Board of OptiBiotix. This follows on from their appointments to the Company in January.
As previously announced on 5 January 2017, Per has many years' experience of the food industry, having worked for some of the world's leading food companies including most recently Cornelius Group plc where he acted as European Director of Health and Nutrition. 
As announced on 18 January 2017, Christina has 25 years' sales experience within the food, nutrition, and nutraceuticals industry. As the owner and CEO of Confoco, a supplier of high quality food ingredients worldwide, Christina grew the business from 1m to 11m sales by obtaining strategic supplier status with multiple global corporates including Nestl, Danone, and Heinz.
Christina Mary Wood
Pursuant to Rule 17 and Schedule Two (g) of the AIM Rules, the following information is disclosed in respect of Christina Mary Wood (aged 57):
Current Appointments 
Appointments in the last 5 years
-
John Morley (Importers) Limited

Confoco International Limited
There is no other information regarding Christina Wood required to be disclosed under the AIM Rules.
Per Rehn
Pursuant to Rule 17 and Schedule Two (g) of the AIM Rules, the following information is disclosed in respect of Per Rehn (aged 47):
Current Appointments 
Appointments in the last 5 years
-
Cornelius Group Plc

Cornelius Nordic APS

Custom Fiber Europe N.V. 

Rehn Consult 2014 ApS

DJAP Holdings ApS

K/S Welford Place

Welford Place Komplementar ApS
Mr Rehn was a director of DJAP Holdings ApS which was placed into liquidation in October 2016 having been dormant for a period of two years and subsequently in November 2016 was placed in insolvency procedures due to an outstanding balance of circa 2,000.
Mr Rehn was a director of K/S Welford Place between May 2010 and March 2016. In March 2016, the company was placed into voluntary liquidation.
Mr Rehn was a director of Welford Place Komplementar ApS between May 2010 and March 2016. In March 2016, the Company was placed into voluntary liquidation and dissolved thereafter.
There is no other information regarding Per Rehn required to be disclosed under the AIM Rules.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information:
OptiBiotix Health plc
www.optibiotix.com
Stephen O'Hara, Chief Executive
ContactviaWalbrookbelow


Cairn Financial Advisers LLP
Tel: 020 7213 0880
Liam Murray / Jo Turner



finnCap (Broker)
Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)

Tony Quirke (Corporate Broking)



Walbrook PR Ltd
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com 
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
BOADMGMFDDKGNZM